Antibody avidity-based approach to estimate population-level incidence of hepatitis C

Antibody avidity-based approach to estimate population-level incidence of hepatitis C

Accurate HCV incidence estimates are critical for monitoring progress towards HCV elimination goals, including an 80% reduction in HCV incidence by 2030. Moreover, incidence estimates can help guide prevention and treatment programming, particularly in the context of the US opioid epidemic. An inexp...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of hepatology 2020-08, Vol.73 (2), p.294-302
Hauptverfasser: Boon, Denali, Bruce, Veronica, Patel, Eshan U., Quinn, Jeffrey, Srikrishnan, Aylur K., Shanmugam, Saravanan, Iqbal, Syed, Balakrishnan, Pachamuthu, Sievers, Matthew, Kirk, Gregory D., Thomas, David L., Quinn, Thomas C., Cox, Andrea L., Page, Kimberly A., Solomon, Sunil S., Mehta, Shruti H., Laeyendecker, Oliver
Format: Artikel
Sprache:eng
Schlagworte:
Antibodies
Avidity
CD4 antigen
Genotypes
HCV
Hepatitis
Hepatitis C
HIV
HIV/HCV coinfection
Human immunodeficiency virus
Immunoglobulin G
Incidence
Infections
Opioids
Population
Recent infection
Ribonucleic acid
RNA
Seroconversion
Surveillance
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Accurate HCV incidence estimates are critical for monitoring progress towards HCV elimination goals, including an 80% reduction in HCV incidence by 2030. Moreover, incidence estimates can help guide prevention and treatment programming, particularly in the context of the US opioid epidemic. An inexpensive, Genedia-based HCV IgG antibody avidity assay was evaluated as a platform to estimate cross-sectional, population-level primary HCV incidence using 1,840 HCV antibody and RNA-positive samples from 875 individuals enrolled in 5 cohort studies in the US and India. Using samples collected
ISSN:0168-8278
1600-0641
DOI:10.1016/j.jhep.2020.03.028